BioProgress restructures dosage technology licence with FMC
Speciality pharma and healthcare business, BioProgress is restructuring its licensing agreement with partner FMC Corporation for its oral drug delivery technology, NRobeT.
Speciality pharma and healthcare business, BioProgress is restructuring its licensing agreement with partner FMC Corporation for its oral drug delivery technology, NRobeT.
This restructuring will facilitate the launch of NRobeT with major pharmaceutical companies on a development and milestone basis. The markets covered by these agreements include combination drug therapies and large molecules and other difficult to formulate oral dosing.
The NRobeT system is a broad-based technology which enhances the stability of existing drugs and is applicable to both small and large molecules.
As part of the new agreement, BioProgress will earn a portion, up to a maximum of 20% of all milestone and royalty income received by FMC on commercialised NRobeT products and supply film, dependent upon agreed performance criteria. BioProgress has agreed to support the development and scale-up of the commercial-scale NRobeT equipment.
In addition, the parties have agreed to explore opportunities that would allow BioProgress to utilise the NRobeT technology for its own developed products that will be marketed by the company's pharmaceutical products division, Dexo BioPharm.